Literature DB >> 34903600

Polypharmacologic Reprogramming of Tumor-Associated Macrophages toward an Inflammatory Phenotype.

Nao Nishida-Aoki1, Taranjit S Gujral2,3.   

Abstract

Tumor-associated macrophages (TAM) are an important component of the tumor microenvironment (TME) that can promote tumor progression, metastasis, and resistance to therapies. Although TAMs represent a promising target for therapeutic intervention, the complexity of the TME has made the study of TAMs challenging. Here, we established a physiologically relevant in vitro TAM polarization system that recapitulates TAM protumoral activities. This system was used to characterize dynamic changes in gene expression and protein phosphorylation during TAM polarization and to screen phenotypic kinase inhibitors that impact TAM programming. BMS-794833, a multitargeted compound, was identified as a potent inhibitor of TAM polarization. BMS-794833 decreased protumoral properties of TAMs in vitro and suppressed tumor growth in mouse triple-negative breast cancer models. The effect of BMS-794833 was independent of its primary targets (MET and VEGFR2) but was dependent on its effect on multiple signaling pathways, including focal adhesion kinases, SRC family kinases, STAT3, and p38 MAPKs. Collectively, these findings underline the efficacy of polypharmacologic strategies in reprogramming complex signaling cascades activated during TAM polarization. SIGNIFICANCE: A physiologically relevant in vitro system of TAM polarization uncovers signaling pathways that regulate polarization and identifies strategies to target macrophage reprogramming to suppress cancer growth. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2021        PMID: 34903600      PMCID: PMC8847322          DOI: 10.1158/0008-5472.CAN-21-1428

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  45 in total

1.  CCL20 Expression by Tumor-Associated Macrophages Predicts Progression of Human Primary Cutaneous Melanoma.

Authors:  Rafael Samaniego; Alejandra Gutiérrez-González; Alba Gutiérrez-Seijo; Sandra Sánchez-Gregorio; Jorge García-Giménez; Enrique Mercader; Iván Márquez-Rodas; José Antonio Avilés; Miguel Relloso; Paloma Sánchez-Mateos
Journal:  Cancer Immunol Res       Date:  2018-01-23       Impact factor: 11.151

2.  Anti-inflammatory roles of p38α MAPK in macrophages are context dependent and require IL-10.

Authors:  Abbas Raza; Jessica W Crothers; Mahalia M McGill; Gary M Mawe; Cory Teuscher; Dimitry N Krementsov
Journal:  J Leukoc Biol       Date:  2017-09-06       Impact factor: 4.962

3.  Re-education of macrophages as a therapeutic strategy in cancer.

Authors:  Joanna Kowal; Mara Kornete; Johanna A Joyce
Journal:  Immunotherapy       Date:  2019-06       Impact factor: 4.196

4.  Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion.

Authors:  Martin Franz Sprinzl; Andreas Puschnik; Anna Melissa Schlitter; Arno Schad; Kerstin Ackermann; Irene Esposito; Hauke Lang; Peter Robert Galle; Arndt Weinmann; Mathias Heikenwälder; Ulrike Protzer
Journal:  J Hepatol       Date:  2014-11-22       Impact factor: 25.083

Review 5.  Src kinases as therapeutic targets for cancer.

Authors:  Lori C Kim; Lanxi Song; Eric B Haura
Journal:  Nat Rev Clin Oncol       Date:  2009-10       Impact factor: 66.675

6.  Tumor-associated macrophages promote invasion while retaining Fc-dependent anti-tumor function.

Authors:  Katharine D Grugan; Francis L McCabe; Michelle Kinder; Allison R Greenplate; Benjamin C Harman; Jason E Ekert; Nico van Rooijen; G Mark Anderson; Jeffrey A Nemeth; William R Strohl; Robert E Jordan; Randall J Brezski
Journal:  J Immunol       Date:  2012-10-26       Impact factor: 5.422

Review 7.  Tumour-associated macrophages as treatment targets in oncology.

Authors:  Alberto Mantovani; Federica Marchesi; Alberto Malesci; Luigi Laghi; Paola Allavena
Journal:  Nat Rev Clin Oncol       Date:  2017-01-24       Impact factor: 66.675

Review 8.  Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy.

Authors:  Michael A Cannarile; Martin Weisser; Wolfgang Jacob; Anna-Maria Jegg; Carola H Ries; Dominik Rüttinger
Journal:  J Immunother Cancer       Date:  2017-07-18       Impact factor: 13.751

9.  Generation of monocyte-derived tumor-associated macrophages using tumor-conditioned media provides a novel method to study tumor-associated macrophages in vitro.

Authors:  Brooke Benner; Luke Scarberry; Lorena P Suarez-Kelly; Megan C Duggan; Amanda R Campbell; Emily Smith; Gabriella Lapurga; Kallie Jiang; Jonathan P Butchar; Susheela Tridandapani; John Harrison Howard; Robert A Baiocchi; Thomas A Mace; William E Carson
Journal:  J Immunother Cancer       Date:  2019-05-28       Impact factor: 13.751

Review 10.  Redefining Tumor-Associated Macrophage Subpopulations and Functions in the Tumor Microenvironment.

Authors:  Kaiyue Wu; Kangjia Lin; Xiaoyan Li; Xiangliang Yuan; Peiqing Xu; Peihua Ni; Dakang Xu
Journal:  Front Immunol       Date:  2020-08-04       Impact factor: 7.561

View more
  3 in total

1.  BMS794833 inhibits macrophage efferocytosis by directly binding to MERTK and inhibiting its activity.

Authors:  Seung-Hyun Bae; Jung-Hoon Kim; Tae Hyun Park; Kyeong Lee; Byung Il Lee; Hyonchol Jang
Journal:  Exp Mol Med       Date:  2022-09-02       Impact factor: 12.153

2.  Implantation of a nerve protector embedded with human GMSC-derived Schwann-like cells accelerates regeneration of crush-injured rat sciatic nerves.

Authors:  Qunzhou Zhang; Justin C Burrell; Jincheng Zeng; Faizan I Motiwala; Shihong Shi; D Kacy Cullen; Anh D Le
Journal:  Stem Cell Res Ther       Date:  2022-06-20       Impact factor: 8.079

3.  Mapping the Tumor Microenvironment in TNBC and Deep Exploration for M1 Macrophages-Associated Prognostic Genes.

Authors:  Baojin Xu; Hefen Sun; Xiaoqing Song; Qiqi Liu; Wei Jin
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.